Collegium Pharmaceutical
COLL
159 hedge funds and large institutions have $668M invested in Collegium Pharmaceutical in 2021 Q4 according to their latest regulatory filings, with 25 funds opening new positions, 50 increasing their positions, 57 reducing their positions, and 19 closing their positions.
1,700% more call options, than puts
Call options by funds: $18K | Put options by funds: $1K
32% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 19
3% more funds holding
Funds holding: 154 → 159 (+5)
1.14% more ownership
Funds ownership: 102.49% → 103.63% (+1.1%)
7% less capital invested
Capital invested by funds: $719M → $668M (-$51M)
12% less repeat investments, than reductions
Existing positions increased: 50 | Existing positions reduced: 57
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Principal Financial Group
Des Moines,
Iowa
|
+$4.84M |
| 2 |
LSV Asset Management
Chicago,
Illinois
|
+$4.19M |
| 3 |
JG
Jefferies Group
New York
|
+$3.14M |
| 4 |
BGIM
Brandywine Global Investment Management
Philadelphia,
Pennsylvania
|
+$3.06M |
| 5 |
SEI Investments
Oaks,
Pennsylvania
|
+$3.01M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$18.5M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$6.33M |
| 3 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$3.73M |
| 4 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
-$3.41M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$2.4M |
COLL Hedge Fund Activity: Q4 2021 in Review
159 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Collegium Pharmaceutical (COLL) for Q4 2021, worth a combined $668M — down 7.1% from $719M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new COLL positions and 19 closed out — a net gain of 6 holders — while 50 added to existing stakes and 57 trimmed.
The largest buyer was Principal Financial Group, adding an estimated $4.84M. The largest seller was Camber Capital Management, cutting an estimated $18.5M.
- 159 institutional investors held Collegium Pharmaceutical (COLL) as of Q4 2021, up from 154 in Q3 2021.
- Funds reported $668M of Collegium Pharmaceutical stock for Q4 2021, down 7.1% quarter-over-quarter.
- 25 funds opened new Collegium Pharmaceutical positions in Q4 2021 and 19 closed out, a net change of +6 holders.
- The largest Collegium Pharmaceutical buyer in Q4 2021 was Principal Financial Group, an estimated $4.84M added.
- The largest Collegium Pharmaceutical seller in Q4 2021 was Camber Capital Management, an estimated $18.5M sold.
Based on aggregated 13F filings for Q4 2021.